<DOC>
	<DOCNO>NCT00730262</DOCNO>
	<brief_summary>The objective study assess efficacy safety TLN-4601 use treat patient Glioblastoma Multiforme ( GBM ) recur/progress receive first line systemic therapy post surgery/radiotherapy .</brief_summary>
	<brief_title>Efficacy Study TLN-4601 Patients With Recurring Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirm Glioblastoma Multiforme ( GBM ) Prior treatment radiation one first line systemic therapy ( include temozolomide chemotherapy , immunotherapy , target therapy combination therapy ) , follow measurable unequivocal evidence tumor progression recurrence Age ≥ 18 year ECOG ≤ 2 Normal organ marrow function define : leukocyte ≥3 x 109/L absolute neutrophil count ≥1.5 x 109/L platelet ≥100 x 109/L hemoglobin ≥90 g/L total bilirubin ≤2.5 X institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) ≤2.5 X institutional upper limit normal creatinine ≤1.0 X institutional upper limit normal Patients life expectancy &lt; 12 week Patients document history HIV , active hepatitis B C infection Female patient pregnant lactate Patients proper central line ( Portacathlike device ) establish Patients know hypersensitivity farnesylated dibenzodiazepinone polysorbate 80 Patients uncontrolled hypotension Patients concomitant therapy therapeutic coumadin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Glioblastoma Multiforme ( GBM )</keyword>
	<keyword>Phase II</keyword>
	<keyword>Brain Cancer</keyword>
</DOC>